Neuraxis (NRXS) Receivables - Net (2022 - 2026)
Neuraxis (NRXS) posted Receivables - Net of $385009.0 for Q1 2026, up 96.73% sequentially from $195703.0 in Q4 2025, and up 57.98% YoY from $243708.0 in Q1 2025.
Neuraxis (NRXS) Receivables - Net (2022 - 2026) Analysis & Trends
Neuraxis has reported Receivables - Net for 5 years, with the latest figure at $385009.0 in Q1 2026.
- Quarterly Receivables - Net rose 57.98% year-over-year to $385009.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $385009.0 (up 57.98% YoY) and the FY2025 annual result came in at $195703.0, down 20.0% from the prior year.
- Receivables - Net climbed to $385009.0 in Q1 2026 per NRXS's latest filing, from $195703.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $385009.0 in Q1 2026 and troughed at $23982.0 in Q4 2023.
- A 5-year average of $156865.4 and a median of $132382.0 in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2023 and 2024: Receivables - Net plunged 86.25% in 2023, then jumped 398.77% in 2024.
- Over 5 years, Receivables - Net stood at $174399.0 in 2022, then slumped by 86.25% to $23982.0 in 2023, then surged by 398.77% to $119616.0 in 2024, then soared by 63.61% to $195703.0 in 2025, then soared by 96.73% to $385009.0 in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $385009.0, $195703.0, and $108504.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 432,925.00 |
| Jun 30, 2026 | 432,925.00 |
| Mar 31, 2026 | 385,009.00 |
| Mar 31, 2026 | 385,009.00 |
| Dec 31, 2025 | 195,703.00 |
| Dec 31, 2025 | 195,703.00 |
| Sep 30, 2025 | 108,504.00 |
| Sep 30, 2025 | 108,504.00 |
| Jun 30, 2025 | 128,518.00 |
| Jun 30, 2025 | 128,518.00 |
| Mar 31, 2025 | 243,708.00 |
| Mar 31, 2025 | 243,708.00 |
| Dec 31, 2024 | 119,616.00 |
| Dec 31, 2024 | 119,616.00 |
| Sep 30, 2024 | 52,594.00 |
| Sep 30, 2024 | 52,594.00 |
| Jun 30, 2024 | 147,131.00 |
| Jun 30, 2024 | 147,131.00 |
| Mar 31, 2024 | 90,534.00 |
| Mar 31, 2024 | 90,534.00 |